Determinants of medication adherence to topical glaucoma therapy

Journal of Glaucoma

Volumn 21, Issue 4, 2012, Pages 234-240

  Dreer, Laura E ^a   Girkin, Christopher ^a   Mansberger, Steven L ^b  

^a School of Medicine   (United Kingdom)

^b DEVERS EYE INSTITUTE   (United States)

Author keywords

compliance; electronic dosing aids; glaucoma; health behaviors; medication adherence; topical glaucoma therapy; Travatan; Travoprost

Indexed keywords

TRAVOPROST;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SOCIOECONOMICS; TOPICAL GLAUCOMA THERAPY; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; AGE FACTORS; ANTIHYPERTENSIVE AGENTS; CONTINENTAL POPULATION GROUPS; DRUG MONITORING; DRUG PRESCRIPTIONS; EDUCATIONAL STATUS; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INCOME; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR;

EID: 84859429275     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e31821dac86     Document Type: Article

References (48)

1. Friedman DS, Wilson MR, Liebmann JM, et al. An evidencebased assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol. 2004; 138:19-31.
2. Quigley H, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90: 262-267. (Pubitemid 43325451)
3. Gordon M, Beiser J, Brandt J, et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120: 714-720. (Pubitemid 34620349)
4. Higginbotham E, Gordon M, Beiser J, et al. The ocular hypertension treatment study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004;122:813-820. (Pubitemid 38736239)
5. Morley AMS, Murdoch I. The future of glaucoma clinics. Br J Ophthalmol. 2006;90:640-645.
6. American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-angle Glaucoma. Limited Revision. San Francisco, CA: American Academy of Ophthalmology; 2003.
7. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713. (Pubitemid 34620348)
8. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120: 1268-1279. (Pubitemid 36105431)
9. Leske MC, Heijl A, Hyman L, et al. Early manifest glaucoma trial: design and baseline data. Ophthalmology. 1999;106: 2144-2153. (Pubitemid 30194238)
10. Nordstrom B, Friedman D, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598.e1-598.e11.
11. Zhou Z, Althin R, Sforzolini B, et al. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004;88:1391-1394. (Pubitemid 39424716)
12. Olthoff C, Schouten JvdB, Websers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review. Ophthalmology 2005;112:953-961. (Pubitemid 40797446)
13. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21:1074-1090. (Pubitemid 29326165)
14. Cronin TH, Kahook MY, Lathrop KL, et al. Accuracy and performance of a commercially available Dosing Aid. Br J Ophthalmol. 2007;91:497-499. (Pubitemid 46623684)
15. Friedman DS, Jampel HD, Congdon NG, et al. The Travatan dosing aid accurately records when drops are taken. Am J Ophthalmol. 2007;143:699-701. (Pubitemid 46452511)
16. Lacey J, Cate H, Broadway D. Barriers to adherence with glaucoma medications: A qualitative research study. Eye. 2008;23:924-932.
17. Tsai J, McClure C, Ramos S, et al. Compliance barriers in glaucoma: A systematic classification. J Glaucoma. 2003;12: 393-398. (Pubitemid 37237370)
18. Friedman D, Hahn S, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma: results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115:1320-1227.
19. Lee P, Kelly S, Mills R, et al. Glaucoma in the United States and Europe: predicting costs and surgical rates based upon stage of disease. J Glaucoma. 2007;16:471-478. (Pubitemid 47263050)
20. Muir KW, Santiago-Turla C, Stinnett SS, et al. Health literacy and adherence to glaucoma therapy. Am J Ophthalmol. 2006; 142:223-223.
21. Kass M, Gordon M, Meltzer D. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol. 1986;101:524-530. (Pubitemid 16114196)
22. Schwartz G. Compliance and persistency in glaucoma followup treatment. Curr Opin Ophthalmol. 2005;16:114-121. (Pubitemid 43790804)
23. Djafari F, Lesk M, Harasymowycz P, et al. Determinants of adherence to glaucoma medical therapy in a long-term patient population. J Glaucoma. 2009;18:238-242.
24. Friedman D, Okeke CO, Jampel H, et al. Risk factors for poor adherence to eye drops in electronically monitored patients with glaucoma. Ophthalmology. 2009;116:1097-1105.
25. Rossi GCM, Pasinetti GM, Scudeller L, et al. Monitoring adherence rates in glaucoma patients using the travatan dosing aid: A 6-month study comparing patients on travoprost 0.004% and patients on travoprost 0.004%/timolol 0.5% fixed combination. Expert Opin Pharmacother. 2010;11:499-504.
26. Huang E, Brown S, Thakur N, et al. Racial/ethnic differences in concerns about current and future medications among patients with type 2 diabetes. Diabetes Care. 2009;32:311-316.
27. Kressin N, Wang F, Long J, et al. Hypertensive patients' race, health beliefs, process of care, and medication adherence. J Gen Intern Med. 2007;22:768-774. (Pubitemid 46763971)
28. Ogedegbe G, Harrison M, Robbins L, et al. Barriers and facilitators of medication adherence in hypertensive African Americans: A qualitative study. Ethn Dis. 2004;14:3-12. (Pubitemid 38262740)
29. Ruppar T, Conn V, Russell C. Medication adherence interventions for older adults: literature review. Res Theory Nurs Pract. 2008;22:114-147.
30. Friedman D, Nordstrom B, et al. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005;112:1500-1504. (Pubitemid 41725403)
31. Rees G, Leong O, Crowston J, et al. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma. Ophthalmology. (In press, corrected proof.)
32. Stryker J, Beck A, Primo S, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010;19:66-72.
33. Tsai J. Medication adherence in glaucoma: Approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17:190-195. (Pubitemid 43790816)
34. Lee B, Sathyan P, John R, et al. Predictors of and barriers associated with poor follow-up in patients with glaucoma in south India. Arch Ophthalmol. 2008;126:1448-1454.
35. Heisler M, Faul J, Hayward R, et al. Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med. 2007;167:1853-1860. (Pubitemid 47481480)
36. Ndumele C, Shaykevich S, et al. Disparities in adherence to hypertensive care in urban ambulatory settings. J Health Care Poor Underserved. 2010;21:132-143.
37. Poon I, Lal L, Ford M, et al. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: A national Cohort Study. Ann Pharmacother. 2009;43:185-193.
38. Trinacty C, Adams A, Soumerai S, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: A longitudinal Cohort Study. BMC Health Serv Res. 2009;9:24.
39. Linda E, Miyong T, Cheryl R, et al. The contexts of adherence for African Americans with high blood pressure. J Adv Nurs. 2000;32:587-594.
40. Barbara J, Christopher H,Mark G, et al. Barriers to adherence and hypertension control in a racially diverse representative sample of elderly primary care patients. Pharmacoepidemiol Drug Saf. 2009;18:672-681.
41. Friedman D, Hahn S, Quigley H, et al. Doctor-patient communication in glaucoma care: Analysis of videotaped encounters in community-based office practice. Ophthalmology. 2009;116:2277-2285.
42. Hahn S. Patient-centered communication to assess and enhance patient adherence to glaucoma medication. Ophthalmology. 2009;116:S37-S42.
43. Okeke C, Quigley H, Jampel H, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116:2286-2293.
44. Berkley-Patton J, Goggin K, Liston R, et al. Adapting effective narrative-based HIV prevention interventions to increase minorities' engagement in HIV/AIDS services. Health Commun. 2009;24:199-209.
45. Comellas M, Walker E, Movsas S, et al. Training community health promoters to implement diabetes self-management support programs for urban minority Adults. Diabetes Educ. 2010;36:141-151.
46. Cooper L, Roter D, Bone L, et al. A randomized controlled trial of interventions to enhance patient-physician partnership, patient adherence and high blood pressure control among ethnic minorities and poor persons: study protocol NCT00123045. Implement Sci. 2009;4:1-16.
47. Hoevenaars J, Schouten J, van den Borne B, et al. Will improvement in knowledge lead to improvement of compliance with glaucoma medication. Acta Ophthalmologica. 2008;86:849-855.
48. Sleath B, Robin A, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006;113:431-436.